December 12, 2024
1 min learn
WASHINGTON — Chimeric antigen receptor nature-killing cell remedy achieved “efficacy, persistence and tremendous security” in a small cohort of sufferers with systemic lupus erythematosus, in line with knowledge introduced at ACR Convergence 2024.
“The distinctive organic traits of NK cells present us with various to deal with SLE with tremendous security,” Qian Hao, PhD, co-founder and CEO of Rui Therapeutics, informed attendees.
“We noticed efficacy, persistence and tremendous security,” Qian Hao, PhD, informed attendees. Picture: Rob Volansky | Healio Rheumatology
Hao introduced findings from 22 sufferers — together with 18 ladies — with energetic extreme and refractory SLE who underwent three doses of KN5501 (Rui Therapeutics), an allogenic CD19-targeting CAR-NK cell remedy following preconditioning with cyclophosphamide and fludarabine.
Assessed outcomes included lupus low illness exercise state (LLDAS), Systemic Lupus Erythematosus Responder Index (SRI) and the 2021 definition of remission in SLE (DORIS). The researchers adopted sufferers for a median period of seven months, with the utmost follow-up at 14 months.
Outcomes at 3 months confirmed an SRI-4 charge of 81%, an SRI-6 charge of 66.7% and an LLDAS charge of 47.6%, in line with the researchers.
At 9 months, SRI-4 and SRI-6 responses had been 100%, with 75% of sufferers reaching LLDAS and half the cohort reaching DORIS response.
“No relapses had been noticed in the course of the follow-up interval,” Hao mentioned.
By 12 months, response charges for all of those outcomes had reached 100%, however knowledge for just one affected person are at the moment accessible.
Wanting deeper into the findings, Hao famous enhancements in serology and illness exercise. “All measures development down,” he mentioned.
Security knowledge indicated no critical incidents of cytokine launch syndrome, immune effector cell-associated neurotoxicity syndrome, infections or critical hostile occasions.
“All 22 sufferers had low doses of glucocorticoids, lower than 10 mg per day, within the ultimate follow-up,” Hao mentioned. “We noticed efficacy, persistence and tremendous security.”
Sources/Disclosures
Collapse
Solar M. Summary #L17. Introduced at: ACR Convergence 2024; Nov. 14-19, 2024; Washington, D.C.
Disclosures:
Hao reviews being CEO of Rui Therapeutics.
